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BACKGROUND: Blood pressure variability (BPV) in midlife increases risk of late- life dementia, but the impact of BPV on the 
cognition of adults who have already reached older ages free of major cognitive deficits is unknown. We examined the risk 
of incident dementia and cognitive decline associated with long- term, visit- to- visit BPV in a post hoc analysis of the ASPREE 
(Aspirin in Reducing Events in the Elderly) trial.
METHODS AND RESULTS: ASPREE participants (N=19 114) were free of dementia and significant cognitive impairment at enroll-
ment. Measurement of BP and administration of a standardized cognitive battery evaluating global cognition, delayed episodic 
memory, verbal fluency, and processing speed and attention occurred at baseline and follow- up visits. Time- to- event analysis 
using Cox proportional hazards regression models were used to calculate hazard ratios (HR) and corresponding 95% CI for 
incident dementia and cognitive decline, according to tertile of SD of systolic BPV. Individuals in the highest BPV tertile com-
pared with the lowest had an increased risk of incident dementia and cognitive decline, independent of average BP and use 
of antihypertensive drugs. There was evidence that sex modified the association with incident dementia (interaction P=0.02), 
with increased risk in men (HR, 1.68; 95% CI, 1.19– 2.39) but not women (HR, 1.01; 95% CI, 0.72– 1.42). For cognitive decline, 
similar increased risks were observed for men and women (interaction P=0.15; men: HR, 1.36; 95% CI, 1.16– 1.59; women: 
HR, 1.14; 95% CI, 0.98– 1.32).
CONCLUSIONS: High BPV in older adults without major cognitive impairment, particularly men, is associated with increased 
risks of dementia and cognitive decline.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT01038583; isrctn.com. Identifier: ISRCTN83772183.
Key Words: blood pressure ■ blood pressure variability ■ cognitive impairment ■ dementia
Increased longevity and a decline in fertility in re-cent decades have led to an aging global popula-tion. It is estimated that people aged 60 years and older will outnumber adolescents and youth by 2050.
1 
As an age- related disease, dementia has become a 
major public health concern worldwide, and the lack of 
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disease- modifying treatments ensures it will indefinitely 
remain a public health priority.
Hypertension is highly prevalent in midlife and is 
a strong risk factor for late- life cognitive decline and 
dementia.2– 4 Although the duration and severity of 
hypertension are important etiologies,2– 7 the short- 
and long- term fluctuation, or variability, of blood 
pressure (BP) has emerged as a novel risk factor for 
cognitive impairment and Alzheimer’s disease.8– 16 
However, previous studies examining high BP vari-
ability (BPV) and cognitive outcomes had limitations. 
These include using a single cognitive assessment 
or instrument,12 analyzing the relationship within 
predominantly younger cohorts,6,7,9– 11,16 in cohorts 
at high risk of cardiovascular disease and receiving 
antihypertensive drugs,14 or in individuals with estab-
lished cognitive impairment.16
Short- term BPV can be ascertained through 24- 
hour BP monitoring, but it is an assessment not 
routinely used in clinical practice.17 Office BPs ac-
cumulated over multiple visits are more readily ac-
cessible, and an estimate of long- term BPV can be 
obtained from these readings.18 In adults who have 
already reached advanced aged with preserved cog-
nition and in otherwise good health, it is unknown 
whether long- term BPV is relevant to predicting their 
cognitive trajectory during their remaining lifespan. 
As a possible clinically actionable biomarker, there 
is a need for research to determine the extent that 
long- term BPV, beyond that of routine BP, can iden-
tify older adults at increased risk of cognitive impair-
ment. Large cohorts with standardized assessments 
of BP and cognition conducted in parallel throughout 
long- term follow- up are required to address this re-
search gap. The ASPREE (Aspirin in Reducing Events 
in the Elderly) study19 is a longitudinal cohort uniquely 
suited to answer this question.
We examined the risk of incident dementia and cog-
nitive decline associated with long- term, visit- to- visit 
BPV in participants of ASPREE, a randomized primary 
prevention trial of daily low- dose aspirin conducted in 
19 114 older adults who were free from dementia, sig-
nificant cognitive impairment, disability, or prior cardio-
vascular disease events, at baseline.
METHODS
The data (version 3.0) that support the findings of 
this study are available from the ASPREE Data 
Coordinating Center, Monash University School of 
Public Health (Aspree.AMS@monash.edu) upon rea-
sonable request.
Study Participants
The detailed methods of ASPREE, its recruitment, and 
primary outcomes have been previously reported.19– 21 
Briefly, ASPREE enrolled community- dwelling adults 
aged 70 years and older from Australia and the United 
States (65 years and older if US minority) from March 
2010 to December 2014 and randomized them to 
aspirin 100 mg daily or matching placebo. At enroll-
ment, participants were free of documented evidence 
of dementia, significant physical disability, prior car-
diovascular events, as well as any medical condi-
tion expected to limit life expectancy to <5  years. 
Individuals with uncontrolled high BP (systolic BP 
≥180  mm  Hg and/or diastolic BP ≥105  mm  Hg), or 
CLINICAL PERSPECTIVE
What Is New?
• We explored the association of long- term,
visit- to- visit blood pressure variability with risk
of incident dementia and cognitive decline
in a generally healthy cohort of older adults
who were enrolled in the ASPREE (Aspirin in
Reducing Events in the Elderly) trial.
• Because ASPREE was not a blood pressure in-
tervention study, and included adults who were
normotensive and hypertensive, investigating
blood pressure variability and its risks in this
cohort potentially increases the generalizability
of the findings to a broader population of older
adults.
What Are the Clinical Implications?
• We observed increased risks of incident de-
mentia and cognitive decline, which were in-
dependent of average blood pressure and use
of antihypertensive drugs, for individuals in the
highest blood pressure variability tertile com-
pared with the lowest.
• There was evidence of interaction by sex, with
men demonstrating the most increased risk
of dementia and cognitive decline; it remains
uncertain whether reducing blood pressure
variability can protect from the development of
cognitive decline.
• Sex is emerging as a key biological variable in
cerebrovascular and cardiovascular research;
our findings highlight the need for further re-
search into the potential mechanisms underly-
ing sex- specific differences in diseases of aging.
Nonstandard Abbreviations and Acronyms
ASPREE Aspirin in Reducing Events in the 
Elderly
BPV blood pressure variability
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a Modified Mini- Mental State Examination score of 
<78 were ineligible. All participants provided writ-
ten informed consent for their participation, and the 
study was approved by institutional review boards in 
both countries. After a median follow- up of 4.7 years, 
aspirin did not extend disability- free survival21— a 
composite of death, incident dementia, or persistent 
physical disability— nor did it lower the risk of cogni-
tive decline.22
Standard Assessments
After completing baseline visits, participants were 
contacted quarterly by telephone and seen annually 
in person for clinical assessments by trained study 
staff following standard operating procedures. These 
assessments gathered data on physical function, life-
style, anthropometrics, cognition, disability, and other 
health parameters, including medical diagnoses and 
prescription medications.
A standardized cognitive battery was adminis-
tered at the baseline and at regular intervals over fol-
low- up visits. The battery consisted of the Modified 
Mini- Mental State Examination for global cogni-
tion,23 the Hopkins Verbal Learning Test- Revised 
for delayed episodic memory,24 the single letter (F) 
Controlled Oral Word Association Test for verbal flu-
ency,25 and the Symbol Digit Modalities Test for pro-
cessing speed and attention.26 The 10- item Center 
for Epidemiologic Studies- Depression scale was 
administered before the cognitive battery to account 
for the possible confounding effect of depression on 
cognitive function.
Assessment of Visit- to- Visit BPV
Blood pressure was measured at each study visit ac-
cording to American Heart Association guidelines, 
in the seated position after at least 5 minutes of rest 
using a validated automated oscillometric device with 
an occluding cuff of appropriate size for the upper arm 
circumference.27 Three separate and consecutive BP 
readings 1  minute apart were taken in a single arm. 
Consistent with the main ASPREE study reports, the 
average of all 3 measurements in each participant was 
recorded as the BP for that visit.
Several methods to estimate BPV have been used 
to characterize both short- term and long- term variabil-
ity, with no universal consensus on the best measure.18 
Long- term, visit- to- visit BPV is usually estimated using 
the SD18; therefore, we estimated BPV initially using 
the within- individual SD of mean systolic BP obtained 
from the baseline, first- , and second- year annual visits. 
Sensitivity analyses were also undertaken to assess 
the robustness of the results, using the coefficient of 
variation and average real variability to estimate BPV, 
as well as expanding the SD estimate of BPV to 4 
measures (baseline, first- , second- , and third- year an-
nual visits), and then analyzing events occurring after 
the third annual visit. Lastly, we also explored the re-
lationship between diastolic BPV and incident demen-
tia and cognitive decline, estimating diastolic BPV in a 
similar manner as our primary BPV estimate.
Cognitive Outcomes
The protocol for clinical adjudication of incident de-
mentia in ASPREE has been reported previously.22 
Suspected dementia “triggers” were identified by a 
Modified Mini- Mental State Examination score <78 or 
a drop of >10.15 points from baseline (adjusted for age 
and education), or medical record report of dementia 
or memory problems, or prescription for cholinesterase 
inhibitor. Following a trigger, additional standardized 
cognitive and functional assessments were conducted 
whenever possible, which included the Alzheimer’s 
Disease Assessment Scale— Cognitive subscale,28 
Color Trails,29 Lurian overlapping figures,30 and the 
Alzheimer Disease Cooperative Study Activities of Daily 
Living Scale.31 Clinical case notes and other supporting 
documentation were also obtained for these demen-
tia triggers. All information was reviewed by an expert 
panel, blinded to treatment arm, who adjudicated the 
dementia end point using the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition criteria.32
Because individuals could experience deterioration 
in cognitive function without meeting the threshold 
for referral for further testing, we also separately ex-
amined a broader outcome of incident cognitive de-
cline. This was defined as a >1.5 SD decline in score 
from an individual’s baseline on any of the cognitive 
tests (Modified Mini- Mental State Examination, Symbol 
Digit Modalities Test, Hopkins Verbal Learning Test- 
Revised delayed recall, and/or Controlled Oral Word 
Association Test) during follow- up and sustained over 
2 testing time points.22
Statistical Analysis
Cox proportional hazards regression models with time- 
to- event analysis were used to calculate hazard ratios 
(HR) and corresponding 95% CI for incident dementia, 
using BPV as a continuous variable, and then according 
to tertile of BPV. The proportional hazards assumption 
was checked using Schoenfeld residuals and found to 
be appropriate. Year 2 was used as the new baseline. 
Tertiles were defined initially for the entire sample and 
then separately for men and women for planned a priori, 
sex- specific analyses. Initial models were adjusted for age 
and sex, followed by additional adjustment for diabetes 
mellitus, depression (10- item Center for Epidemiologic 
Studies- Depression scale score ≥8), body mass index, 
statin use, smoking, dyslipidemia, ethnicity, education, 
and living situation. Analyses were repeated similarly for 
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incident cognitive decline. To minimize immortal time 
bias during the period used to estimate BPV,33 partici-
pants with incident dementia or cognitive decline in the 
first 2 years were excluded from the analysis. The study 
design is shown in Figure S1.
We investigated potential effect modification by 
sex, and antihypertensive drug use,3,34 by including 
a multiplicative interaction term in the models. When 
significance was found, BPV tertiles were redefined 
separately within the subgroups and stratified analyses 
performed. Sensitivity analyses were also conducted 
restricting the analysis to only those participants who 
remained consistently on or off antihypertensive drugs 
during the BPV estimation period, to account for po-
tential variability in BP that could be linked to initiation 
or discontinuation of antihypertensives.35 A 2- sided 
P value of <0.05 was used as the cutoff for statistical 
significance. All analyses were conducted using Stata 
version 16 (StataCorp, College Station, TX).
RESULTS
Among 19  114 individuals originally randomized into 
ASPREE, 16  758 participants remained in the study 
and had mean BP recorded at baseline, year 1, and 
year 2 visits, for estimation of BPV (Figure 1). Of these 
participants, 16 600 were free of dementia at 2 years, 
and 396 cases of incident dementia subsequently oc-
curred over a median follow- up of 2.7 years (95% CI, 
1.6– 3.6). At 2 years, 14 105 participants were free of 
cognitive decline, and 1993 events subsequently oc-
curred over a median follow- up of 2.0 years (95% CI, 
1.0– 3.0). In the initial age and sex- adjusted Cox mod-
els, being in the highest tertile of BPV compared with 
the lowest tertile was associated with an increased risk 
of both incident dementia (HR, 1.33; 95% CI, 1.05– 
1.70) and cognitive decline (HR, 1.21; 95% CI, 1.09– 
1.35) (Figure  S2). However, there was evidence that 
sex modified this association (interaction P=0.02 for 
incident dementia and P=0.15 for cognitive decline). 
As such, all subsequent analyses are presented sepa-
rately for men and women.
Table 1 shows the baseline characteristics according 
to tertiles of BPV of the men and women included 
in the analysis of incident dementia. On average, 
women had higher BPV than men. As tertiles pro-
gressed from lowest to highest, mean age increased 
as did baseline and average systolic BP, and par-
ticipants had more comorbidities such as diabetes 
mellitus, chronic kidney disease, and pack years 
of smoking. Baseline cognitive scores were similar 
across all BPV tertiles for both men and women. 
Characteristics of participants included in the analy-
sis of incident cognitive decline demonstrated mostly 
similar patterns (Table S1).
Following the year 2 visit, incident dementia oc-
curred in 2.6% (188/7318) of men and 2.2% (208/9282) 
of women, whereas incident cognitive decline occurred 
in 14.7% (915/6204) and 13.6% (1078/7901) of men 
and women, respectively (Figure 2). In the multivariate- 
adjusted Cox model, men in the highest tertile of BPV 
Figure 1. Consort flow diagram of participants included in the analysis.



































Died before year 2 visit (n=236)
Withdrew consent before year 2 visit (n=95)
Year 2 visit otherwise not conducted (n=185)
Year 2 visit not conducted in person  (n=1,615)
BP not measured at baseline, year 1 and 2 visits (n=225)
Participated in year 2 visit
n=18,598
Follow-up
Incident dementia at/before 
year 2 visit (n=81)
Otherwise censored (n=77)
Cognitive decline at/before 
year 2 visit (n=608)
No subsequent in-person  
cognitive assessments 
(n=2045)
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were at significantly increased risk of both incident de-
mentia (HR, 1.68; 95% CI, 1.19– 2.39; P=0.004) and cog-
nitive decline (HR, 1.36; 95% CI, 1.16– 1.59; P<0.0001) 
compared with those in the lowest tertile (Table 2). The 
HRs were minimally changed after further adjustment 
for additional covariates including ethnicity, living sta-
tus, smoking, dyslipidemia, or chronic kidney disease. 
Furthermore, these associations remained consistent 




T1, n=2503 T2, n=2401 T3, n=2414 T1, n=3117 T2, n=3083 T3, n=3082
SD of SBP, mean (SD) 4.2 (1.6) 9.0 (1.4) 16.6 (4.4) 4.4 (1.7) 9.4 (1.4) 17.4 (5.0)
Baseline SBP, mm Hg, mean (SD) 137.9 (13.8) 140.5 (14.8) 145.0 (17.8) 133.6 (14.5) 136.4 (15.6) 142.6 (18.7)
Baseline diastolic blood pressure, mm Hg, 
mean (SD)
77.2 (8.9) 77.9 (9.3) 79.2 (10.3) 75.3 (9.5) 76.3 (9.8) 78.2 (11.0)
Baseline antihypertensive medications, 
n (%)
1116 (44.6) 1090 (45.4) 1360 (56.3) 1509 (48.4) 1665 (54.0) 1887 (61.2)
Average SBP* over blood pressure 
variability period, mean (SD)
137.7 (13.4) 139.4 (13.1) 141.9 (13.0) 133.3 (14.0) 135.6 (13.6) 139.7 (13.5)
Ethno- racial group, n (%)
Australian White 2240 (89.5) 2152 (89.6) 2141 (88.7) 2666 (85.5) 2616 (84.9) 2592 (84.1)
US White 114 (4.6) 101 (4.2) 87 (3.6) 204 (6.5) 225 (7.3) 208 (6.8)
Black 69 (2.8) 65 (2.7) 71 (2.9) 131 (4.2) 143 (4.6) 169 (5.5)
Hispanic/Latino 52 (2.1) 43 (1.8) 61 (2.5) 82 (2.6) 67 (2.2) 70 (2.3)
Other 28 (1.1) 40 (1.7) 54 (2.2) 34 (1.1) 32 (1.0) 43 (1.4)
Age, y, n (%)
65– 73 1366 (54.6) 1263 (52.6) 1175 (48.7) 1701 (54.6) 1540 (50.0) 1392 (45.2)
≥74 1137 (45.4) 1138 (47.4) 1239 (51.3) 1416 (45.4) 1543 (50.1) 1690 (54.8)
Education y, n (%)
<12 1096 (43.8) 1034 (43.1) 1038 (43.0) 1460 (46.8) 1385 (44.9) 1433 (46.5)
12– 15 657 (26.3) 657 (27.4) 671 (27.8) 899 (28.8) 967 (31.4) 922 (29.9)
16+ 750 (30.0) 710 (29.6) 705 (29.2) 758 (24.3) 731 (23.7) 727 (23.6)
Alcohol, n (%)
Current 2096 (83.7) 2044 (85.1) 2013 (83.4) 2264 (72.6) 2229 (72.3) 2226 (72.2)
Former 173 (6.9) 153 (6.4) 167 (6.9) 150 (4.8) 122 (4.0) 150 (4.9)
Never 234 (9.4) 204 (8.5) 234 (9.7) 703 (22.6) 732 (23.7) 706 (22.9)
Body mass index, kg/m2, mean (SD) 27.9 (3.9) 27.9 (3.9) 28.1 (4.0) 28.1 (5.0) 28.1 (5.2) 28.4 (5.3)
Living alone, n (%) 482 (19.3) 456 (19.0) 519 (21.5) 1246 (40.0) 1275 (41.4) 1323 (42.9)
Current or past smoker, n (%) 1372 (54.8) 1330 (55.4) 1415 (58.6) 1080 (34.7) 1040 (33.7) 1067 (34.6)
Smoking pack years, mean (SD) 24.3 (27.7) 24.5 (25.5) 25.2 (25.4) 17.7 (20.2) 18.0 (18.9) 18.8 (21.5)
Diabetes mellitus, n (%) 265 (10.6) 291 (12.1) 331 (13.7) 270 (8.7) 246 (8.0) 304 (9.9)
Depression, n (%) 181 (7.2) 176 (7.3) 181 (7.5) 358 (11.5) 320 (10.4) 348 (11.3)
Dyslipidemia, n (%) 1392 (55.6) 1328 (55.3) 1326 (54.9) 2275 (73.0) 2233 (72.4) 2282 (74.0)
Chronic kidney disease, n (%) 507 (21.9) 545 (24.4) 643 (28.6) 702 (24.1) 704 (24.5) 878 (30.6)
Statin medications, n (%) 712 (28.5) 663 (27.6) 675 (28.0) 1025 (32.9) 1010 (32.8) 1084 (35.2)
Aspirin treatment assignment, n (%) 1249 (49.9) 1186 (49.4) 1189 (49.3) 1572 (50.4) 1516 (49.2) 1523 (49.4)
Pulse pressure, mean (SD) 60.7 (12.1) 62.6 (12.4) 65.9 (14.3) 58.2 (12.9) 60.1 (13.6) 64.3 (15.2)
Heart rate, mean (SD) 69.2 (10.4) 69.0 (11.0) 68.5 (11.1) 72.6 (9.9) 72.0 (10.2) 71.2 (10.6)
SD of heart rate variability, mean (SD) 5.4 (3.5) 5.7 (3.9) 6.2 (4.2) 5.0 (3.4) 5.3 (3.6) 5.7 (3.8)
Cognitive performance
Modified Mini- Mental State Examination, 
mean (SD)
93.2 (4.5) 92.8 (4.7) 92.9 (4.6) 94.3 (4.3) 94.2 (4.2) 94.2 (4.3)
Hopkins Verbal Learning Test- Revised 
delayed recall, mean (SD)
7.3 (2.8) 7.3 (2.9) 7.3 (2.8) 8.3 (2.7) 8.4 (2.7) 8.3 (2.7)
 (Continued)
J Am Heart Assoc. 2021;10:e019613. DOI: 10.1161/JAHA.120.019613 6
Ernst et al Long- Term BP Variability and Cognition
after exclusion of men with a stroke or myocardial infarc-
tion during the trial (data not shown). In women, there 
was no significant association between tertile of BPV 
and incident dementia (HR, 1.01; 95% CI, 0.72– 1.42; 
P=0.96) or cognitive decline (HR, 1.14; 95% CI, 0.98– 
1.32; P=0.09). When BPV was treated as a continuous 
variable, the findings in men and women remained con-
sistent (Table 2).
In sensitivity analysis limiting the cohort to individ-
uals who remained consistently on or off antihyper-
tensive drugs throughout the period when BPV was 
estimated, an additional 729 men and 752 women 
from the analysis of incident dementia, and 617 men 
and 648 women from the analysis of cognitive decline, 
were excluded. The results, however, remained con-
sistent with the main findings, showing an increased 
Figure 2. Cumulative incidence of events according to blood pressure variability tertile; dementia incidence in men (A); 
dementia incidence in women (B); incidence of cognitive decline in men (C); and incidence of cognitive decline in women (D).
BPV indicates blood pressure variability; and T, tertile.
Characteristic
Men Women
T1, n=2503 T2, n=2401 T3, n=2414 T1, n=3117 T2, n=3083 T3, n=3082
Symbol Digit Modalities Test, mean (SD) 36.4 (9.6) 35.9 (9.9) 35.1 (9.9) 38.8 (9.8) 38.7 (10.0) 37.6 (10.1)
Controlled Oral Word Association Test, 
mean (SD)
11.7 (4.5) 11.5 (4.5) 11.6 (4.5) 12.6 (4.6) 12.7 (4.5) 12.7 (4.5)
Age was categorized based on the median age of participants, which was 74 years. Ethno- racial group was based on self- report. Other ethno- racial group 
was defined as any category with less than 200 participants overall, which included Aboriginal or Torres Strait Islander, Native American, multiple races or 
ethnic groups, Native Hawaiian or Pacific Islander, and those who indicated that they were not Hispanic but did not state another race or ethnic group. Diabetes 
mellitus was defined as a participants’ report of diabetes mellitus or a fasting glucose level of ≥126 mg per deciliter (≥7 mmol per liter) or receipt of treatment for 
diabetes mellitus. Depression was defined as a 10- item Center for Epidemiological Studies Depression Scale score of ≥8. Dyslipidemia was defined as serum 
cholesterol level of ≥212 mg per deciliter (≥5.5 mmol per liter) in Australia and ≥240 mg per deciliter (≥6.2 mmol per liter) in the United States or as a low- density 
lipoprotein level of >160 mg per deciliter (>4.1 mmol per liter); or taking cholesterol- lowering medication. Chronic kidney disease was defined as estimated 
glomerular filtration rate <60 mL/min per 1.73 m2 or albumin to creatinine ratio ≥3 mg/mmol. ASPREE indicates Aspirin in Reducing Events in the Elderly; BPV, 
blood pressure variability; SBP, systolic blood pressure; and T, tertile.
*Over the period in which BPV was measured, thus baseline to the second annual visit.
Table 1. Continued
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risk of incident dementia and cognitive decline for men 
in the highest tertile of BPV compared with the lowest 
tertile but not in women (Table S2).
We further explored the relationship between use of 
antihypertensive drugs and the cognitive end points. In 
men but not women, there was a significant interaction 
between antihypertensive use and BPV for both incident 
dementia (P=0.01) and cognitive decline (P=0.02). Men 
in the highest tertile who were not on antihypertensive 
drugs during the BPV estimation period were not at in-
creased risk of dementia (HR, 0.83; 95% CI, 0.48– 1.43; 
P=0.51), whereas men in the middle and highest tertiles 
who were consistently on antihypertensive drugs were at 
increased risk (T2: HR, 2.11; 95% CI, 1.14– 3.91; P=0.02; 
T3: HR, 2.97; 95% CI, 1.65– 5.34; P<0.001) (Table  3). 
Likewise, men using antihypertensives in the highest ter-
tile had an increased risk of cognitive decline relative to 
those in the lowest tertile (HR, 1.68; 95% CI, 1.34– 2.12; 
P<0.001), but no such association was seen for the sec-
ond tertile. Treating BPV as a continuous variable re-
sulted in similar findings.
In sensitivity analyses using alternate BPV indices, 
the observed relationships were consistent with our 
primary analysis (Table S3). Further sensitivity analysis 
using BPV calculated from 4 measurements (baseline, 
year 1, 2, and 3 visits) and restricting to events that 
occurred after the year 3 visit, produced similar results 
for dementia in men, but cognitive decline was no lon-
ger significant (Table  S4). For comparative purposes 
we also examined the association between other BP 
measures and incident dementia and cognitive decline 
in the cohort. The results indicated that none of the 
measures— systolic or diastolic BP, high BP, or use 
of antihypertensive drug— were associated with ei-
ther dementia or cognitive decline in men or women 
(Table S5). Lastly, we did not observe any significant 





Age Adjusted Multivariate Adjusted*
HR 95% CI P Value HR 95% CI P Value
Dementia
Men 7318 188
BPV (continuous) 1.33 1.12– 1.60 0.002 1.33 1.11– 1.60 0.002
BPV tertile
Tertile 1 2503 51 Reference Reference
Tertile 2 2401 48 0.94 0.64– 1.40 0.77 0.96 0.65– 1.43 0.84
Tertile 3 2414 89 1.68 1.19– 2.38 0.003 1.68 1.19– 2.39 0.004
Women 9282 208
BPV (continuous) 1.00 0.85– 1.19 0.96 1.00 0.85– 1.19 0.98
BPV tertile
Tertile 1 3117 60 Reference Reference
Tertile 2 3083 73 1.03 0.73– 1.44 0.88 1.03 0.74– 1.45 0.85
Tirtile 3 3082 75 1.01 0.72– 1.41 0.96 1.01 0.72– 1.42 0.96
Cognitive decline
Men 6204 915
BPV (continuous) 1.02 1.00– 1.03 0.007 1.02 1.01– 1.03 0.005
BPV tertile
Tertile 1 2107 305 Reference Reference
Tertile 2 2043 258 0.99 0.84– 1.17 0.92 1.00 0.85– 1.19 0.97
Tertile 3 2054 352 1.34 1.14– 1.56 <0.0001 1.36 1.16– 1.59 <0.0001
Women 7901 1078
BPV (continuous) 1.01 1.00– 1.02 0.06 1.01 1.00– 1.02 0.10
BPV tertile
Tertile 1 2672 336 Reference Reference
Tertile 2 2608 327 0.98 0.84– 1.14 0.76 0.98 0.84– 1.14 0.81
Tertile 3 2621 415 1.15 0.99– 1.32 0.07 1.14 0.98– 1.32 0.09
BPV indicates blood pressure variability; and HR, hazard ratio.
*Adjusted for age, average systolic blood pressure, antihypertensive medications at baseline, education, diabetes mellitus, depression, body mass index,
and statin medications.
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association between diastolic BPV and incident de-
mentia or cognitive decline (Table S6).
DISCUSSION
In this post hoc analysis of ASPREE participants with-
out dementia, those in the highest tertile of BPV com-
pared with the lowest were at significantly increased 
risk of incident dementia and cognitive decline during 
follow- up, independent of mean systolic BP. Sex and 
use of antihypertensive drugs modified this associa-
tion, whereby the risk of incident dementia and cog-
nitive decline appeared greatest in men who were 
receiving antihypertensive treatment. These findings 
remained consistent in sensitivity analyses, which in-
cluded restricting the cohort to those without change 
in antihypertensive drug use during the BPV estimation 
period and use of alternate estimates of BPV.
Our findings support previous work establishing 
BPV as an independent risk factor for cognitive im-
pairment.8– 15,36 However, our work expands this un-
derstanding to older, relatively healthy adults (including 
those without hypertension) who had reached late life 
without significant cognitive impairment; a group that 
is not typically considered at high risk for dementia in 
their remaining lifespan. Furthermore, our results also 
provide the first evidence of possible sex- specific ef-
fects of BPV on cognition. Although we and others 
have found that women have higher BPV than men,37,38 
to our knowledge, none considered whether the asso-
ciation between BPV and cognitive impairment differs 
between men and women.
The pathobiological mechanisms connecting in-
creased BPV with cognitive decline and dementia have 
not been fully established. Accumulating evidence 
suggests BPV is associated with structural brain 
changes, including increased white matter hyperinten-
sities, cerebral microbleeds, and enlarged perivascular 
spaces.39– 42 The basal forebrain cholinergic neuronal 
degeneration and associated presynaptic choliner-
gic denervation in Alzheimer’s disease may influence 
sympathetic and parasympathetic autoregulation of 
BP, contributing to BPV. The resultant hemodynamic 
instability can increase shear stress and promote mi-
crovascular damage, which may affect permeability of 
the blood brain barrier and accelerate neuronal injury.43 
Although all ASPREE participants were without major 
cognitive deficits at baseline, we cannot exclude the 
possibility that subclinical disease was present and 
contributed via this pathway.
We considered several explanations for why men, 
but not women, were at increased risk for dementia 
and cognitive impairment in our analysis. It may reflect 
higher cumulative burden from traditional midlife vas-
cular risk factors that are the strongest risk for late- life 
dementia. These include BP4,43 and smoking,44 and 
men in our study did have higher exposures to both, 
yet our findings persisted after adjustment for these 
covariates. Increased vascular stiffness is associated 
with cognitive decline,45 and stroke and myocardial in-
farction are manifestations of the underlying vascular 
risk burden. However, we observed similar pulse pres-
sures in men and women, and our associations re-
mained consistent after exclusion of men with a stroke 
or myocardial infarction during the trial.
Table 3. Cumulative Incidence of Dementia and Cognitive Decline According to BPV in Men, Stratified by Antihypertensive 






Events HR* 95% CI P Value
No. of 
Events HR* 95% CI P Value
Dementia 3111 70 3478 92
BPV (continuous) 0.97 0.93– 1.02 0.29 1.06 1.03– 1.09 <0.0001
BPV tertile
Tertile 1 1055 28 Ref. 1178 15 Ref.
Tertile 2 1019 16 0.58 0.31– 1.08 0.09 1146 31 2.11 1.14– 3.91 0.02
Tertile 3 1037 26 0.83 0.48– 1.43 0.51 1154 46 2.97 1.65– 5.34 <0.0001
Cognitive decline 2665 377 2922 439
BPV (continuous) 0.99 0.97– 1.01 0.44 1.02 1.01– 1.04 0.002
BPV tertile
Tertile 1 906 128 Ref. 992 124 Ref.
Tertile 2 875 120 1.03 0.80– 1.32 0.84 959 125 1.05 0.82– 1.35 0.71
Tertile 3 884 129 1.02 0.79– 1.30 0.89 971 190 1.68 1.34– 2.12 <0.0001
BPV indicates blood pressure variability; and HR, hazard ratio.
*Adjusted for age, average systolic blood pressure, education, diabetes mellitus, depression, body mass index, and statin medications.
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The possibility of different underlying pathways for 
cognitive decline in men and women exists, perhaps 
based partly on timing of risk factor exposure, as sex- 
specific associations with late- life cognition have been 
previously reported.46,47 Furthermore, the cerebrovas-
culature is affected by sex hormones, which may lead 
to differences in how cerebral blood vessels function 
under both physiological and pathological conditions.48 
The effect of estrogen exposure, either through longer 
endogenous estrogen exposure or hormone therapy, 
is one such possibility. Although hormone therapy did 
not benefit cognition in the Women’s Health Initiative,49 
other research suggests that longer endogenous es-
trogen exposure and hormone therapy are associated 
with higher cognitive status in late life.50,51 The age of 
women in ASPREE would suggest that many went 
through menopause at a time when hormone ther-
apy was more widespread, and it is possible they had 
higher lifetime estrogen exposure.
We observed that the association between high 
BPV and cognitive decline and dementia was stron-
gest in men who reported using antihypertensive 
drugs during the 2 years in which BPV was assessed. 
Some possibilities to explain this finding include that 
antihypertensive use may be a proxy for underlying 
vascular risk, and men in our cohort could have had 
longer durations of hypertension or were more poorly 
controlled. Indeed, it has been shown that intensive 
blood pressure control with antihypertensives re-
duces the risk of mild cognitive impairment.52 Poor 
adherence to antihypertensives influences visit- to- 
visit BPV,35 and men in our cohort could have been 
less adherent to their treatments. Although we can-
not offer a definitive explanation for the sex- based 
differences, our results should not be interpreted as 
to suggest that antihypertensive treatment in men 
is harmful to their cognitive trajectory. Sex is clearly 
emerging as a key biological variable in cerebrovas-
cular and cardiovascular research.48,53 Our findings 
highlight the need for more research investigating the 
potential mechanisms underlying sex- specific differ-
ences in diseases of aging and further support the 
consideration of potential sex- related differences in 
clinical practice and in the design of future trials.
Strengths and Limitations
The large sample size, administration of a compre-
hensive cognitive battery at multiple study visits, 
standardized BP assessments, and adjudicated 
dementia diagnoses are key strengths of our study. 
The cohort’s inclusion of individuals with and with-
out hypertension expands its generalizability to 
older adults not receiving interventions such as ag-
gressive BP lowering that may affect the underly-
ing causal pathway for dementia.52 In contrast to 
previous studies,36 we chose a more conservative 
analysis by only considering cognitive decline and 
dementia end points occurring after the period dur-
ing which BPV was estimated. Although minimiz-
ing immortal time bias, this approach potentially 
reduces the precision around effect size estimates 
because it excludes events occurring early in the 
study. We also conducted multiple sensitivity analy-
ses that further supported the results. Finally, the 
lack of significant association of the cognitive end 
points with any of the other traditional BP meas-
ures adds further strength to the concept of BPV as 
an independent risk factor for cognitive decline and 
dementia.
Our study has important limitations we acknowl-
edge. It is a post hoc analysis whose findings can be 
subject to unmeasured confounders. We were un-
able to account for adjustments to antihypertensive 
regimens or nonadherence, although our sensitivity 
analyses limiting the cohort to those consistently on 
or off antihypertensives during the BPV estimation 
period did not alter the findings. Reverse causation 
is also a possibility, because greater BPV may stem 
from dysfunctional autoregulation of BP in those with 
cortical atrophy, and we cannot exclude the possi-
bility that subclinical disease was present at base-
line in some individuals. The sex- related differences 
observed could reflect inadequate statistical power, 
as fewer women experienced dementia or cognitive 
impairment during the follow- up period. We were un-
able to account for lifetime estrogen exposure, which 
may have influenced the sex- related differences ob-
served.50 Finally, our findings are associative, and 
only a well- designed prospective intervention trial 
can establish whether high BPV is a viable therapeu-
tic target to lower the risk of cognitive decline and 
dementia.
CONCLUSIONS
In adults who have reached older ages free of evidence 
of dementia or major cognitive impairment, high BPV 
was independently associated with increased risk of 
dementia and cognitive decline, particularly in men. 
Future research should investigate sex- specific ef-
fects of high BPV on cognition and prospectively test 
whether reducing BPV preserves late- life cognitive 
function.
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SUPPLEMENTAL MATERIAL 
Table S1. Baseline characteristics of ASPREE participants included in the cognitive decline analysis, by sex and 
tertiles of blood pressure variability (n=14,150). 
Characteristic Men Women 
T1, n=2,107 T2, n=2,043 T3, n=2,054 T1, n=2,672 T2, n=2,608 T3, n=2,621 
Standard deviation of systolic blood pressure, mean 
(SD) 
4.3 (1.6) 9.0 (1.4) 16.5 (4.4) 4.4 (1.7) 9.4 (1.4) 17.4 (5.0) 
Baseline systolic blood pressure, mmHg, mean (SD) 138.0 (14.0) 140.3 (14.8) 145.0 (17.7) 133.3 (14.6) 136.7 (15.8) 142.6 (18.7) 
Baseline diastolic blood pressure, mmHg, mean (SD) 77.3 (9.0) 77.9 (9.3) 79.3 (10.3) 75.4 (9.5) 76.5 (9.8) 78.3 (11.1) 
Baseline antihypertensive medications, n (%) 934 (44.3) 915 (44.8) 1144 (55.7) 1303 (48.8) 1410 (54.1) 1598 (61.0) 
Average systolic blood pressurea over BPV period, 
mean (SD) 
137.8 (13.6) 139.4 (13.1) 142.0 (12.9) 133.1 (14.1) 135.9 (13.8) 139.7 (13.5) 
Ethno-racial group, n (%) 
Australian white 1889 (89.7) 1822 (89.2) 1834 (89.3) 2278 (85.3) 2234 (85.7) 2220 (84.7) 
U.S. white 98 (4.7) 90 (4.4) 77 (3.8) 185 (6.9) 189 (7.3) 182 (6.9) 
African-American 56 (2.7) 58 (2.8) 50 (2.4) 119 (4.5) 110 (4.2) 131 (5.0) 
Hispanic/Latino 39 (1.9) 35 (1.7) 46 (2.2) 63 (2.4) 47 (1.8) 53 (2.0) 
Other  25 (1.2) 38 (1.9) 47 (2.3) 27 (1.0) 28 (1.1) 35 (1.3) 
Age, y, n (%) 
65-73 1132 (53.8) 1066 (52.2) 997 (48.5) 1460 (54.6) 1275 (48.9) 1170 (44.6) 
≥ 74 975 (46.3) 977 (47.8) 1057 (51.5) 1212 (45.4) 1333 (51.1) 1451 (55.4) 
Education y, n (%) 
<12 946 (44.9) 885 (43.3) 873 (42.5) 1269 (47.5) 1176 (45.1) 1220 (46.6) 
12-15 540 (25.6) 565 (27.7) 566 (27.6) 773 (29.0) 814 (31.2) 777 (29.7) 
16+ 621 (29.5) 593 (29.0) 615 (29.9) 630 (23.6) 618 (23.7) 624 (23.8) 
Alcohol, n (%) 1769 (84.0) 1732 (84.8) 1726 (84.0) 1969 (73.7) 1888 (72.4) 1901 (72.5) 
Current 139 (6.6) 123 (6.0) 135 (6.6) 120 (4.5) 101 (3.9) 120 (4.6) 
Former 199 (9.4) 188 (9.2) 193 (9.4) 583 (21.8) 619 (23.7) 600 (22.9) 
Never 
Body Mass Index, kg/m2, mean (SD) 27.9 (3.8) 27.9 (3.9) 28.0 (3.9) 28.0 (5.0) 28.0 (5.2) 28.4 (5.3) 
Living alone, n (%) 399 (18.9) 386 (19.0) 432 (21.0) 1052 (39.4) 1074 (41.2) 1123 (42.9) 
Current or past smoker, n (%) 1152 (54.7) 1120 (54.8) 1208 (58.8) 895 (33.5) 861 (33.0) 909 (34.7) 
Smoking Pack Years, mean (SD) 23.8 (27.3) 24.9 (25.8) 24.8 (25.8) 17.4 (20.1) 18.0 (19.1) 18.5 (19.3) 
Diabetes, n (%) 223 (10.6) 249 (12.2) 270 (13.2) 224 (8.4) 194 (7.4) 238 (9.1) 
Depression, n (%) 149 (7.1) 143 (7.0) 141 (6.9) 308 (11.5) 255 (9.8) 293 (11.2) 
Dyslipidemia, n (%) 1180 (56.0) 1127 (55.2) 1126 (54.8) 1959 (73.3) 1892 (72.6) 1952 (74.5) 
Chronic Kidney Disease, n (%) 441 (22.6) 464 (24.4) 547 (28.6) 601 (24.0) 602 (24.8) 744 (30.4) 
Statin medications, n (%) 590 (28.0) 561 (27.5) 571 (27.8) 893 (33.4) 853 (32.7) 926 (35.3) 
Aspirin treatment assignment, n (%) 1052 (49.9) 1033 (50.6) 1042 (50.7) 1320 (49.4) 1324 (50.8) 1303 (49.7) 
Characteristic Men Women 
T1, n=2,107 T2, n=2,043 T3, n=2,054 T1, n=2,672 T2, n=2,608 T3, n=2,621 
Pulse Pressure, mean (SD) 60.7 (12.1) 62.4 (12.3) 65.7 (14.2) 57.9 (12.9) 60.2 (13.8) 64.2 (15.2) 
Heart Rate, mean (SD) 69.4 (10.5) 68.9 (11.1) 68.4 (11.1) 72.6 (9.8) 72.2 (10.2) 71.3 (10.7) 
Standard deviation of heart rate variabilitya, mean (SD) 5.4 (3.5) 5.7 (3.9) 6.1 (4.1) 5.0 (3.4) 5.3 (3.7) 5.6 (3.8) 
Cognitive Performance 
3MS, mean (SD) 93.2 (4.5) 92.8 (4.7) 92.9 (4.6) 94.5 (4.2) 94.3 (4.2) 94.2 (4.3) 
HVLT-R delayed recall, mean (SD) 7.4 (2.8) 7.3 (2.9) 7.3 (2.8) 8.4 (2.6) 8.4 (2.7) 8.3 (2.7) 
SDMT, mean (SD) 36.3 (9.6) 35.8 (9.6) 35.0 (9.7) 38.9 (9.7) 38.6 (9.8) 37.5 (9.9) 
COWAT, mean (SD) 11.6 (4.4) 11.5 (4.5) 11.6 (4.5) 12.7 (4.7) 12.7 (4.4) 12.7 (4.5) 
aOver the period in which blood pressure variability was measured, baseline to the second annual visit. 
Age was categorised based on the median age of participants, which was 74 years. 
Ethno-racial group was based on self-report. Other ethno-racial group was defined as any individual category with less than 200 participants overall, which included Aboriginal or 
Torres Strait Islander, Native American, Native Hawaiian or Pacific Islander, multiple races or ethnic groups. 
Diabetes was defined as a participants’ report of diabetes mellitus or a fasting glucose level of ≥126 mg per deciliter (≥7 mmol per liter) or receipt of treatment for diabetes.  
Depression was defined as a Center for Epidemiological Studies Depression Scale 10 (CES-D-10) score of ≥8. 
Dyslipidemia was defined as serum cholesterol level of ≥212 mg per deciliter (≥5.5 mmol per liter) in Australia and ≥240 mg per deciliter (≥6.2 mmol per liter) in the U.S. or as a low-
density lipoprotein level of > 160 mg per deciliter (>4.1 mmol per liter); or taking cholesterol-lowering medication.  
Chronic Kidney Disease was defined as eGFR < 60 ml/min/1.73m2 or albumin to creatinine ratio ≥3mg/mmol. 
SD: standard deviation. 
Table S2. Adjusted association between blood pressure variability (BPV) and incident dementia and cognitive 
decline in men and women, restricting the sample to only those participants whose use (or non-use) of 
antihypertensives was stable during the period when BPV was defined (from baseline to annual visit 2). 
Men Women 
N N, events HR 95% CI P N N, events HR 95% CI P 
Incident Dementia 6589 162 8530 187 
T1 2375 46 Ref. 2914 61 Ref. 
T2 2161 42 0.97 0.64-1.48 0.89 2852 58 0.92 0.64-1.32 0.65 
T3 2103 74 1.63 1.12-2.38 0.01 2764 68 1.01 0.71-1.43 0.97 
Incident Cognitive Decline 5587 816 7273 980 
T1 1952 265 Ref. 2493 321 Ref. 
T2 1840 243 0.98 0.82-1.17 0.81 2409 301 0.97 0.83-1.13 0.69 
T3 1795 308 1.32 1.12-1.57 0.001 2351 358 1.10 0.94-1.32 0.24 
Adjusted for age, average systolic blood pressure, anti-hypertensive medications from baseline to annual visit 2, education, diabetes, depression, BMI, and statin medications. 
HR: Hazard Ration; 95% CI: 95% Confidence Interval. 
Table S3. Adjusted association between BPV estimated using average real variability (ARV) and coefficient of 
variation (CV) and incident dementia and cognitive decline in men and women.  
Men Women 
N N, events HR 95% CI P N N, events HR 95% CI P 
Incident Dementia 7318 188 9282 208 
ARV, T1 2627 48 Ref. 3326 77 Ref. 
ARV, T2 2330 51 1.16 0.78-1.73 0.45 3001 67 0.95 0.68-1.32 0.75 
ARV, T3 2361 89 1.86 1.30-2.66 0.001 2955 64 0.83 0.59-1.17 0.28 
CV, T1 2442 50 Ref. 3095 67 Ref. 
CV, T2 2439 49 0.99 0.64-1.42 0.81 3094 71 1.01 0.72-1.41 0.97 
CV, T3 2437 89 1.67 1.18-2.37 0.004 3093 70 0.94 0.67-1.31 0.71 
Incident Cognitive Decline 6204 915 7901 1078 
ARV, T1 2237 309 Ref. 2830 358 Ref. 
ARV, T2 1958 249 0.92 0.78-1.09 0.31 2556 346 0.93 0.80-1.08 0.33 
ARV, T3 2009 357 1.29 1.10-1.51 0.001 2515 374 1.10 0.95-1.28 0.19 
CV, T1 2068 275 Ref. 2634 347 Ref. 
CV, T2 2068 286 1.04 0.88-1.23 0.61 2635 326 0.93 0.80-1.08 0.33 
CV, T3 2068 354 1.28 1.09-1.50 0.002 2632 405 1.10 0.95-1.28 0.19 
Adjusted for age, average systolic blood pressure, anti-hypertensive medications at baseline, education, diabetes, depression, BMI, and statin medications. 
Table S4. Adjusted association between blood pressure variability estimated from four time-points (baseline, 
annual visit 1, 2 and 3) and incident dementia (n=14,052) and cognitive decline (n=7,980) occurring after annual 
visit 3.  
Men Women 
N N, events HR 95% CI P N N, events HR 95% CI P 
Incident Dementia 6184 110 7868 117 
T1 2073 23 Ref. 2632 39 Ref. 
T2 2053 35 1.38 0.82-2.34 0.23 2614 37 0.91 0.58-1.44 0.70 
T3 2058 52 1.94 1.18-3.21 0.009 2622 41 0.85 0.54-1.33 0.47 
Incident Cognitive Decline 3460 454 4520 559 
T1 1002 132 Ref. 1510 161 Ref. 
T2 1008 147 1.02 0.81-1.30 0.84 1504 185 1.13 0.91-1.40 0.26 
T3 976 175 1.18 0.93-1.48 0.17 1506 213 1.22 0.99-1.51 0.07 
Adjusted for age, average systolic blood pressure, anti-hypertensive medications at baseline, education, diabetes, depression, BMI, and statin medications. 
Table S5. Cox proportional hazards analysis for the association between blood pressure related measures and 
incident dementia and cognitive decline in men and women. 
Baseline characteristics Men Women 
HR 95% CI P HR 95% CI P 
Incident Dementia 
Anti-hypertensive medications 1.14 0.86-1.52 0.37 1.12 0.85-1.48 0.42 
High blood pressure (>140/90 mmHg) 0.95 0.71-1.26 0.70 0.93 0.71-1.23 0.62 
Systolic blood pressure (mm Hg) 1.00 0.99-1.01 0.47 1.00 0.99-1.01 0.76 
High systolic blood pressure (≥140 mm Hg) 0.95 0.72-1.27 0.75 0.92 0.70-1.21 0.55 
Diastolic blood pressure (mm Hg) 0.99 0.98-1.01 0.43 1.00 0.98-1.01 0.58 
High diastolic blood pressure (≥90 mm Hg)  0.96 0.62-1.51 0.88 1.00 0.67-1.52 0.98 
Incident Cognitive Decline 
Anti-hypertensive medications 1.09 0.96-1.24 0.20 1.08 0.96-1.22 0.23 
High blood pressure (>140/90 mmHg) 1.02 0.89-1.16 0.78 0.99 0.88-1.12 0.86 
Systolic blood pressure (mm Hg) 1.00 1.00-1.00 0.89 1.00 1.00-1.01 0.55 
High systolic blood pressure (≥140 mm Hg) 1.02 0.90-1.16 0.76 1.00 0.89-1.13 0.95 
Diastolic blood pressure (mm Hg) 1.00 0.99-1.00 0.42 1.00 0.99-1.00 0.34 
High diastolic blood pressure (≥90 mm Hg) 1.07 0.89-1.29 0.48 0.90 0.75-1.08 0.24 
Adjusted for age 
Table S6. Cox proportional hazards analysis for the association between diastolic blood pressure variability and 
incident dementia and cognitive decline.  
Adjusted age Multivariate adjusted 
BPV Tertiles N N, events HR 95% CI P HR 95% CI P 
DEMENTIA 
Men (n=7318) 
T1 2648 63 Ref. Ref. 
T2 2451 56 0.89 0.61-1.29 0.53 0.86 0.59-1.24 0.41 
T3 2218 69 1.18 0.84-1.65 0.35 1.15 0.82-1.62 0.42 
Women (n=9282) 
T1 3049 52 Ref. Ref. 
T2 3011 68 1.12 0.79-1.60 0.52 1.17 0.79-1.59 0.54 
T3 3222 88 1.31 0.94-1.83 0.12 1.31 0.95-1.84 0.12 
COGNITIVE DECLINE 
Men (n=6204) 
T1 2237 308 Ref. Ref. 
T2 2064 282 0.97 0.82-1.14 0.71 0.97 0.83-1.14 0.71 
T3 1887 316 1.07 0.92-1.26 0.37 1.08 0.92-1.26 0.34 
Women (n=7901) 
T1 2550 329 Ref. Ref. 
T2 2562 339 0.94 0.81-1.09 0.44 0.95 0.82-1.10 0.46 
T3 2773 400 0.97 0.84-1.13 0.71 0.96 0.83-1.11 0.59 
aAdjusted for age, average systolic blood pressure, anti-hypertensive medications at baseline, education, diabetes, depression, BMI, and statin 
medications.  
Figure S1. Study design showing the period when blood pressure variability (BPV) was measured, and 
assessment of incident dementia and cognitive decline. 
BPV was defined as the standard deviation of mean systolic blood pressure at baseline, year 1 and year 2 visits. For this analysis, 
individuals with cognitive decline or dementia before the year 2 annual visit were excluded, and dementia incidence and cognitive 
decline was assessed from year 2 onwards.  
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